Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Synthetic lethality is an effective antitumor strategy identified through large-scale genetic screening.
• Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle and are implicated in synthetic lethality.
• CDKs exhibit synthetic lethality with oncogenes like MYC, TP53, and RAS, offering therapeutic potential.

Purpose of the Study:

• To review the synthetic lethal phenotypes and mechanisms involving CDKs.
• To summarize preclinical and clinical findings on CDK inhibitors.
• To explore the future prospects of CDK inhibitors in synthetic lethality-based cancer therapy.

Main Methods:

• Literature review of synthetic lethality screens.
• Analysis of genetic interactions between CDKs and oncogenes.
• Summary of preclinical and clinical data for CDK inhibitors.

Main Results:

• CDKs are frequently identified as synthetic lethal partners with common oncogenes.
• Numerous CDK inhibitors have demonstrated preclinical efficacy.
• Several CDK inhibitors are currently in clinical trials for various cancers.

Conclusions:

• CDK-related synthetic lethality presents a promising avenue for novel cancer treatments.
• Targeting CDKs offers a strategic approach for synthetic lethality-based antitumor therapies.
• Further research and clinical development of CDK inhibitors are warranted.